A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR)

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a non-interventional web based registry designed to assess demographic, treatment and outcomes data in patients receiving treatment with long-acting injectable risperidone. One year retrospective data and 2 year prospective data will be collected.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Korea, Ltd., Korea
• Treatments: Risperidone

Criteria

Inclusion Criteria:

• Patients starting treatment with a new antipsychotic medication

• Permitted by their physician to participate in a clinical trial

• Patients with schizophrenia or schizoaffective disorder

• Patients who are an ambulant or not chronically hospitalized for maximal 6 months at the moment of initiation of study

• Patients and/or his/her relative, guardian or legal representative has signed the informed consent form

Exclusion Criteria:

• First antipsychotic treatment ever

• Participating in any other drug study

• Chronically hospitalized and according to physician no possibility of being discharged within the planned observation period

• On clozapine during the last 3 months

• Serious unstable medical condition, including recent and present clinically relevant laboratory abnormalities

• Previous sensitivity history to risperidone and treatment resistant schizophrenia

• Pregnant or breast-feeding female

• Female with planned pregnancy within two years